Veronica Covalesky is a Cardiology physician affiliated with Philadelphia University. OpenAlex indexes 24 publications with 576 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1703 S Broad St
Suite 300
Phila, PA 19148
Telephone
215-463-5333Provider last certified this registry record 7 Jul 2023.
Clinical trials
- A Prospective Analysis To Assess The Potential Use Of ECGio In Clinical Practice
Sponsor: Heart Input Output Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Cleerly, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.2%Adenosine Receptor Agonist18%Regadenoson100%Part B, office-administered≥377 patientsStatin17.4%Rosuvastatin Calcium59%Atorvastatin Calcium36%Pravastatin Sodium3%Pitavastatin Calcium2%Part D<11 patients+ 21 more classes in this area
Blood & clotting
10.6%Factor Xa inhibitor4.4%Eliquis63%Xarelto37%Part D≥56 patientsPlatelet Aggregation Inhibitor4%Dipyridamole100%Part B, office-administered≥47 patients+ 3 more classes in this area
Metabolism & gastrointestinal
7.8%GLP-1 receptor agonist2.9%Ozempic58%Wegovy28%Mounjaro14%Part D<11 patientsSGLT2 inhibitor1.6%Farxiga45%Jardiance44%Dapagliflozin11%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 800.01 Artificial Intelligence Analysis of A 12-Lead Digital ECG Predicts Angiographically Significant Left Main Coronary Artery Disease
JACC: Cardiovascular Interventions
2026 - TCT-898 A PET-CT verified AI Algorithm to predict the ischemic impact of Coronary Artery Disease
Journal of the American College of Cardiology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”